SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Recursion Pharmaceuticals appoints Fred Hassan as Chair

Item 2.02 Reports results, Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Board increased from 9 to 10 members
  2. Fred Hassan appointed as Class II Director
  3. Hassan to receive cash and equity compensation
  4. No material interest or arrangements disclosed

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025